The annual meeting of the American Society of Clinical Oncology (ASCO), will kick off on June 4. Featuring presentations on the latest ground-breaking science in oncology, this event is always a must-attend for anyone involved in developing better treatments for cancer.
This year ASCO is more relevant than ever considering the effects of the COVID-19 pandemic on cancer patients and oncology clinical research. The pandemic has had serious consequences for cancer patients. According to an article published in the Journal of the National Cancer Institute[i] cancer patients who contracted COVID-19 had a 23% risk of mortality compared to a 6% risk for non-cancer patients. In patients treated with chemotherapy, surgery or immunotherapy, the case fatality rate was 25.6%, 27.6% and 24.3%, respectively. The pandemic also caused delays in screening programs and patients receiving diagnoses.
The COVID-19 pandemic has also had a huge impact on oncology clinical trials causing major disruptions and delays to studies all over the world. A study published in The Lancet in early 2021 found that there was “a 60% decrease in new cancer clinical trials and biological therapies during the COVID-19 pandemic 2020”[ii]. Issues relating to patient enrollment, logistics problems and patient safety were cited as the key obstacles to continuing trials and establishing new trials throughout 2020. After an initial period in early 2020 when almost all trials were paused or halted, the clinical research sector found ways to get research back on track by using virtual and hybrid models of clinical trials allowing for remote monitoring. As many developed countries are now emerging from the pandemic and entering a recovery phase, hopes are high that oncology research can rebound to deliver more innovative treatments to patients.
Cromos Pharma is looking forward to ASCO 2021, to learn more about emerging treatments and how the sector is responding to the pandemic-related challenges.
Cromos Pharma has extensive experience in managing all aspects of clinical trials in oncology in all Phases, I, II, III and post market/observational. Oncology studies represent nearly 20% of our work and we have successfully managed 100+ studies in oncology from breast cancer to hematology-oncology. Regulatory inspections and site audits attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
Global expertise combined with in-depth experience and knowledge in Central and Eastern Europe.
Extensive PI/site network and unparalleled access to patient databases and key opinion leaders.
Unrivalled record for patient recruitment – our team has met or reduced enrollment timelines in 95% of trials conducted over our sixteen year history.
Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program.
Optimized start-up timelines in our regions e.g. we achieve regulatory approvals in the Republic of Georgia, within two months of project signing (In Russia, 4 months, and in Ukraine, less than 5 months).
Find out more about Cromos Pharma’s oncology expertise and how we can support your next clinical study by emailing firstname.lastname@example.org.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.